GILD

Gilead Sciencesの空売り状況は、投資家がGilead Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Gilead Sciences (NASDAQ:GILD) 株価情報, 空売り情報

GILEAD SCIENCES INC

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

Time Magazine&#8217;s annual 100 Most Influential Companies list for 2025 includes many companies investors are familiar with, with numerous names originating from the growing <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence sector.</a>
The <a href="https://time.com/7297630/time-reveals-the-2025-time100-most-influential-companies-in-the-world/">list</a> seeks to honor the top businesses that are helping "chart an essential path forward."
"No single data point or financial metric makes a TIME100 Company. Instead, we looked at a mosaic of qualities, studying impact, innovation, ambition, and success, each in the forms that take shape today. And as we say for all TIME100 projects: influence comes in many forms, for better and for worse," Time editors said of the list.
 The Public Companies: Similar to the list of the <a href="https://www.benzinga.com/general/entertainment/25/04/44854679/time-100-most-influential-people-includes-elon-musk-mark-zuckerberg-alex-karp-and-more-public-company-ceos">Most Influential People</a> that Time published earlier this year, the list of influential companies includes top tech, AI, crypto, and healthcare names that are experiencing impressive growth and bringing life-changing technology to consumers or other companies.
Here is the list of publicly traded companies or those that are part of a publicly traded company. It is broken down by the key groups used by Time: Innovators, Disruptors, Leaders, Titans and Pioneers.
Innovators
<ul class="wp-block-list">
<li>On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>): footwear</li>
<li>Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>): Chinese e-commerce</li>
<li>Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>): video games</li>
<li>BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>): electric vehicles</li>
<li>Gap, unit of Gap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>): apparel</li>
<li>Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>): sports and outdoor retailer</li>
<li>EssilorLuxottica (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESLOY#OTC">ESLOY</a>): sunglasses, optical wear</li>
</ul>
Disruptors
<ul class="wp-block-list">
<li>Waymo, unit of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Life Time Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>): fitness centers</li>
<li>Elf Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): beauty products</li>
<li>Poppi, unit of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): beverages</li>
<li>UFC, unit of TKO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>): fighting sports league</li>
<li>Pop Mart (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PMRTY#OTC">PMRTY</a>): pop culture retailer</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): cryptocurrency trading platform</li>
<li>SharkNinja Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>): home appliances</li>
</ul>
Leaders
<ul class="wp-block-list">
<li>Engie (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ENGIY#OTC">ENGIY</a>): energy company</li>
<li>Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>): industrial and logistics real estate</li>
<li>Cloudflare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NET#NASDAQ">NET</a>): a software company</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): biotechnology, healthcare</li>
<li>Duolingo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): mobile learning</li>
<li>BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): financials</li>
<li>Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>): automotives</li>
<li>LinkedIn, unit of Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): social networking</li>
<li>Coursera Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>): online learning</li>
</ul>
Titans
<ul class="wp-block-list">
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): conglomerate</li>
<li>Comcast, NBC Universal, units of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): media and entertainment</li>
<li>L'Oreal (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LRLCY#OTC">LRLCY</a>): beauty company</li>
<li>DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>): food delivery</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): social networking</li>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): a software company</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): e-commerce</li>
<li>Arm Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>): semiconductors</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): consumer products</li>
<li>Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): financial technology</li>
<li>MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): Latin American e-commerce</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>): retailer</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): streaming</li>
<li>Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>): semiconductors</li>
<li>Universal Music Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNVGY#OTC">UNVGY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>): music publishing</li>
</ul>
Pioneers
<ul class="wp-block-list">
<li>ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>): semiconductors</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>): oil and gas</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): medical devices</li>
<li>Softbank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>): telecom and e-commerce conglomerate</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): gene editing</li>
</ul>
Read Also: <a href="https://www.benzinga.com/general/social-media/24/09/40760039/elon-musk-less-influential-to-artificial-intelligence-than-scarlett-johansson-time-magazine-">Elon Musk Less Influential To Artificial Intelligence Than Scarlett Johansson, Time Magazine Says: Billionaire Brushes Off Exclusion – &#8216;Magazines Do Not Establish Relevance, History Does&#8217;</a>
Why It's Important: Nearly half of this year's list includes companies that are publicly traded or part of publicly traded companies. This means investors can get exposure to what Time considers some of the most influential companies in the world.
Some of the companies are newer to the public market, which could mean that the 50+ companies that are not yet public could be among IPOs to watch for in the second half of 2025 and beyond.
Some of the most recognizable private companies on this year's list include OpenAI, Polymarket, Anthropic, Anduril, Beast Industries and SpaceX.
When seeking companies that can drive revenue growth and gain customer and consumer adoption, the most influential lists can be a valuable starting point for investors.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/03/44367926/mark-cuban-kevin-oleary-rejected-poppi-on-shark-tank-pepsi-just-paid-1-9-billion-to-acquire-company">Mark Cuban, Kevin O&#8217;Leary Rejected Poppi On Shark Tank, Pepsi Just Paid $1.9 Billion To Acquire Company</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

Media

Trading Ideas

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COIN

COUR

CRSP

DASH

DUOL

ENGIY

EQNR

ESLOY

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PLTR

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$103.00</td>
<td>$76.5K</td>
<td>1.3K</td>
<td>6.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$110.00</td>
<td>$98.1K</td>
<td>12</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$28.4K</td>
<td>4.0K</td>
<td>707</td>
</tr>
<tr>
<td>SMLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>161</td>
<td>657</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on June 27, 2025. Parties traded 494 contract(s) at a $103.00 strike. This particular put needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $76.5K, with a price of $155.0 per contract. There were 1365 open contracts at this strike prior to today, and today 6023 contract(s) were bought and sold. 
• Regarding VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we observe a call option sweep with bearish sentiment. It expires in 51 day(s) on August 15, 2025. Parties traded 249 contract(s) at a $110.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $98.1K, with a price of $389.0 per contract. There were 12 open contracts at this strike prior to today, and today 1001 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option sweep with bullish sentiment. It expires in 51 day(s) on August 15, 2025. Parties traded 200 contract(s) at a $30.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $142.0 per contract. There were 4078 open contracts at this strike prior to today, and today 707 contract(s) were bought and sold. 
• Regarding SMLR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), we observe a call option sweep with neutral sentiment. It expires in 86 day(s) on September 19, 2025. Parties traded 34 contract(s) at a $40.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $760.0 per contract. There were 161 open contracts at this strike prior to today, and today 657 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SMLR

VRNA

4 Health Care Stocks With Whale Alerts In Today's Session

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2), with broad <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">oncology treatment potential</a>.
CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
Kymera can receive up to $750 million in total payments, including up to $85 million in upfront and potential <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46091245/gilead-sciences-and-kymera-therapeutics-enter-into-exclusive-option-and-license-agreement-to-devel" rel="noreferrer noopener">option exercise payments</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
In addition, Kymera may receive tiered royalties ranging from the high single-digits to the mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program.
If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture, and commercialize all products resulting from the collaboration.
The transaction with Kymera is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2025 EPS by approximately $0.02-$0.03.
The core of this collaboration lies in the innovative approach of MGDs. Unlike traditional inhibitors that merely block the function of disease-driving proteins, MGDs work by selectively eliminating these proteins.
As Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences, stated, this mechanism &#8220;aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue.&#8221;
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics, highlighted that their &#8220;highly specific, orally active, CDK2 molecular glue degraders have demonstrated a compelling preclinical profile.&#8221;
Concurrently, Kymera Therapeutics announced an update on its IRAK4 partnership with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent, and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46091325/kymera-therapeutics-announces-sanofi-irak4-collaboration-update" rel="noreferrer noopener">into clinical studies</a>.
Following preclinical work supporting its development potential, KT-485 is being prioritized for development under the companies&#8217; existing IRAK4 collaboration and is expected to advance into Phase 1 testing next year.
Based on the planned development of KT-485, Sanofi <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30076238/kymera-therapeutics-stock-jumps-after-positive-data-from-atopic-dermatitis-trial" rel="noreferrer noopener">will not advance KT-474</a>.
Sanofi was conducting Phase 2 trials for hidradenitis suppurativa and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39675035/kymera-announces-expansion-of-kt-474-sar444656-hs-and-ad-phase-2-studies-following-interim-review-" rel="noreferrer noopener">atopic dermatitis indications</a>.
In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the companies&#8217; collaboration agreement terms.
Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485.
Kymera can receive up to $975 million of potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.
Price Action: SNY stock is down 0.76% at $48.05, KYMR stock is down 4.54% at $45, and GILD stock is down 0.28% at $106.90 during the premarket session at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46093513/sam-altman-crushes-openai-microsoft-feud-rumors-hails-really-wonderfully-good-bond-with-satya-nadella" target="_blank" rel="noreferrer noopener">Sam Altman Crushes OpenAI-Microsoft Feud Rumors, Hails &#8216;Really Wonderfully Good&#8217; Bond With Satya Nadella</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

News

Health Care

Movers

General

KYMR

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Gilead Sciences And Kymera Enter Into Exclusive Option And License Agreement To Accelerate Development And Commercialization Of MGD Program Targeting CDK2 With Broad Oncology Treatment Potential Including In Breast Cancer And Other Solid Tumors

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.59% on an annualized basis producing an average annual return of 12.01%. Currently, Gilead Sciences has a market capitalization of $132.09 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,798.39 today based on a price of $106.19 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750713324_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Yeztugo&nbsp;(lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">who need or want PrEP</a>.
Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative. 
The first PrEP medication, which was also developed by Gilead, was approved in the <a href="https://www.benzinga.com/pressreleases/25/06/b46004872/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months" target="_blank" rel="noreferrer noopener">U.S. in 2012</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45982235/gileads-hiv-prevention-drug-could-be-manufactured-at-shocking-low-cost-report" rel="noreferrer noopener">Gilead&#8217;s HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report</a>
In the&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Ffull-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024&amp;esheet=54257682&amp;newsitemid=20250520465880&amp;lan=en-US&amp;anchor=PURPOSE+1+trial&amp;index=4&amp;md5=75b8ce4877adca4271276392d97406cf" rel="noreferrer noopener">PURPOSE 1 trial</a>, data at the primary analysis showed twice-yearly subcutaneous Yeztugo demonstrated zero HIV infections among 2,134 participants in the Yeztugo group, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral Truvada&nbsp;(emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF)&nbsp;in cisgender women in sub-Saharan Africa.
In the&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Fgilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow&amp;esheet=54257682&amp;newsitemid=20250520465880&amp;lan=en-US&amp;anchor=PURPOSE+2+trial&amp;index=6&amp;md5=9249be8d81ad64a52dab27c8a0a16b25" rel="noreferrer noopener">PURPOSE 2 trial</a>, there were two HIV infections among 2,179 participants in the twice-yearly subcutaneous Yeztugo group, demonstrating 99.9% of participants in the Yeztugo group did not acquire HIV infection and superiority of prevention of HIV infections when compared with once-daily oral Truvada.
In both trials, Yeztugo, the company&#8217;s injectable HIV-1 capsid inhibitor, also demonstrated superiority in the prevention of HIV infections when compared with background HIV incidence (bHIV)&nbsp;and was generally well-tolerated, with no significant or <a target="_blank" href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" rel="noreferrer noopener">new safety concerns identified</a>.&nbsp;
In the U.S., Gilead is working closely with insurers, healthcare systems and other payers to ensure broad insurance coverage for Yeztugo. Additionally, for eligible commercially insured individuals with commercial insurance, Gilead&#8217;s Advancing Access&nbsp;Co-Pay Savings Program will reduce out-of-pocket costs to as little as zero dollars.
Gilead has submitted a marketing authorization application (MAA) and EU-Medicines for all (EU-M4all) applications with the European Medicines Agency (EMA),&nbsp;both of which the EMA has validated&nbsp;and will review under an accelerated assessment timeline.
Gilead has also filed for regulatory approval for twice-yearly lenacapavir for PrEP with authorities in Australia,&nbsp;Brazil, Canada, and&nbsp;South Africa.
<h2 class="wp-block-heading">Pricing</h2>
Citing an <a target="_blank" href="https://www.cnbc.com/2025/06/18/fda-approves-gilead-hiv-prevention-injection-lenacapavir.html" rel="noreferrer noopener">email</a> from a Gilead spokesperson, CNBC noted that Yeztugo&#8217;s annual list price in the U.S. before insurance is $28,218.
A month&#8217;s supply of Truvada and Descovy, Gilead&#8217;s daily pills for PreP, are both around $2,000 without insurance, which amounts to around $24,000 per year.
One dose of GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Apretude, which is taken once monthly for the first two months and then once every other month thereafter, costs <a target="_blank" href="https://viivuspricing.com/apretude.html" rel="noreferrer noopener">roughly $4,000</a> before insurance.
Winnie Byanyima, Executive Director of UNAIDS and United Nations Undersecretary-General, <a href="https://www.eatg.org/hiv-news/unaids-urges-gilead-to-drop-price-of-new-hiv-prevention-shot/" target="_blank" rel="noreferrer noopener">said</a>, &#8220;Lenacapavir could be the tool we need to bring new infections under control, but only if it is priced affordably and made available to everyone who could benefit.&#8221;
&#8220;UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of rollout. It is beyond comprehension how Gilead can justify a price of $28,218. If this game-changing medicine remains unaffordable, it will change nothing&#8230;,&#8221; Byanyima added.
AIDS Healthcare Foundation President Michael Weinstein sharply criticized Gilead&#8217;s outrageous pricing, <a target="_blank" href="https://www.businesswire.com/news/home/20250618031796/en/AHF-Gileads-Greed-Kills-Promise-of-Lenacapavir-for-HIV-Prevention" rel="noreferrer noopener">saying</a>, &#8220;What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead&#8217;s greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV.&#8221;
Price Action: GILD stock is trading higher by 1.16% to $109.25 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44284430/merck-plans-regulatory-submission-for-two-drug-regime-for-hiv-infection-by-mid-2025" target="_blank" rel="noreferrer noopener">Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025</a></li>
</ul>
Photo by Tada Images via Shutterstock

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

WIIM

GILD stock has given up its prior gain. Gilead shares were trading higher after the company received FDA approval for Yeztugo, the first and only twice-yearly injectable for HIV pre-exposure prophylaxis

Gilead shares are trading higher after the company received FDA approval for Yeztugo, the first and only twice-yearly injectable for HIV pre-exposure prophylaxis

<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf" title="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf</a>

Gilead Receives FDA Approval Of Yeztugo, The First And Only Twice-Yearly Injectable For The Prevention Of HIV As Pre-Exposure Prophylaxis

Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is facing mounting pressure to price its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">long-acting HIV prevention</a> drug, lenacapavir, affordably as it prepares for U.S. regulatory approval on June 19.
In December 2022, the FDA <a target="_blank" href="https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv" rel="noreferrer noopener">approved</a> Lenacapavir in combination with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.
Researchers and global health leaders are urging the company to ensure widespread access, especially in low- and middle-income countries, given the drug&#8217;s potential to significantly curb the HIV pandemic.
Also Read: <a href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" target="_blank" rel="noreferrer noopener">Gilead&#8217;s HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug</a>
In June 2024, Gilead Sciences shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial, indicating its twice-yearly lenacapavir&nbsp;demonstrated 100% efficacy for the investigational use of HIV <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39416579/why-is-gilead-sciences-stock-trading-higher-on-thursday" rel="noreferrer noopener">prevention in cisgender women</a>, marking a major shift from daily oral pre-exposure prophylaxis (PrEP) regimens. However, concerns are rising about affordability.
While Gilead has not yet disclosed the price, it is expected to align with existing preventive medications at approximately $25,000 annually. As a treatment for those already living with HIV, the drug costs around $39,000 per year.
Citing a new analysis from the University of Liverpool, the Guardian report <a href="https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead" target="_blank" rel="noreferrer noopener">suggests</a> that if produced at a large scale, lenacapavir could be manufactured for as little as $25 annually, even with a 30% profit margin.
Dr. Andrew Hill, one of the study&#8217;s authors, argued that charging over $20,000 a year would make widespread use unfeasible, even in wealthy countries.
He added that updated production estimates show lenacapavir could be made for $35 to $46 per year at 2 million doses annually and as low as $25 at volumes between 5 million and 10 million doses.
Earlier, Hill estimated that a generic version of lenacapavir could be produced for $40 a year, assuming 10 million <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash" rel="noreferrer noopener">people used it annually</a>.
In October 2024, Gilead partnered with <a target="_blank" href="https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries" rel="noreferrer noopener">six</a> generic manufacturers to supply low-cost versions in 120 low-income countries.
The Guardian report added that the company has pledged to deliver doses to about 2 million people at no profit ahead of generic availability.
Despite these commitments, advocates have criticized the exclusion of key countries with high HIV burdens, such as Brazil, Argentina, and parts of Eastern Europe, from Gilead&#8217;s licensing agreements.
Last week, the U.S. Food and Drug Administration <a target="_blank" href="https://www.gilead.com/company/company-statements/2025/gilead-provides-update-on-clinical-studies-evaluating-gs-1720-and-or-gs-4182-for-the-treatment-of-hiv-1-infection" rel="noreferrer noopener">placed</a> a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor).
The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Price Action: GILD stock is trading lower by 2.22% to $108.37 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44284430/merck-plans-regulatory-submission-for-two-drug-regime-for-hiv-infection-by-mid-2025" target="_blank" rel="noreferrer noopener">Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025</a></li>
</ul>
Image via Shutterstock

Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report

<a href="https://ca.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4058215" title="https://ca.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4058215">https://ca.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4058215</a>

'FDA Places Clinical Hold On Gilead's HIV Treatment Trials Of GS-1720 And/Or GS-4182; Hold Due To Identification Of Safety Signal Of Decreases In CD4+T-Cell & Absolute Lymphocyte Counts In Subset Of Participants Getting Combo; Intend To Investigate And Pursue Potential Of Both Agents And Work With Regulatory Authorities To Resolve Issues' - Investing

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) New Drug Application (NDA) submissions for lenacapavir — the company&#8217;s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">exposure prophylaxis (PrEP)</a>.
What Happened: The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target <a href="https://www.benzinga.com/pressreleases/25/02/b43780305/u-s-fda-accepts-gileads-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-unde" target="_blank" rel="noreferrer noopener">action date of June 19, 2025</a>.
In June 2024, Gilead Sciences shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial, indicating its twice-yearly lenacapavir&nbsp;demonstrated 100% efficacy for the investigational use of HIV <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39416579/why-is-gilead-sciences-stock-trading-higher-on-thursday" rel="noreferrer noopener">prevention in cisgender women</a>.
Based on these results, the independent Data Monitoring Committee (DMC) recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
Since June last year, Gilead stock has gained almost 74%, and year-to-date stock has jumped around 21%.
In March, Gilead Sciences&nbsp;presented data from its HIV treatment portfolio and pipeline at the&nbsp;Conference on Retroviruses and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" rel="noreferrer noopener">Opportunistic Infections&nbsp;(CROI 2025)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44907790/gilead-cancer-drug-combined-with-mercks-drug-effective-in-difficult-to-treat-type-of-breast-cancer" rel="noreferrer noopener">Gilead Cancer Drug Combined With Merck&#8217;s Drug Effective In Difficult To Treat Type Of Breast Cancer</a>
With the breakthrough, Wall Street is paying attention again.
The company, a leader in HIV treatment, is showing signs of a successful turnaround. Despite this momentum, its stock is still relatively cheap, trading at 13.3 times forward earnings — less than the pharmaceutical industry average of 14.
Why It Matters: Some investors may worry that Gilead is repeating history. About 10 years ago, its stock surged due to the success of a cure for hepatitis C, but later, it declined as demand faded. Since then, slow growth and disappointing cancer drug deals hurt its image, making it seem like a value trap.
This time could be different — but Gilead has to deliver.
Over 400,000 Americans use PrEP. To reach $4 billion in annual sales, citing some analysts, the Wall Street Journal <a href="https://www.wsj.com/health/pharma/a-new-shot-prevents-hivand-breathes-new-life-into-a-stagnant-biotech-6badbce9" target="_blank" rel="noreferrer noopener">report</a> expects that by 2030, Gilead must get more people on the drug and grow the market globally. The company aims to more than double U.S. PrEP users to over one million in the next 10 years.
Unlike other drugmakers facing upcoming patent expirations, Gilead is well-positioned. Its HIV drug Biktarvy, used after infection, is protected from generic competition until 2033.
It also has several next-generation HIV treatments in development, supporting its future growth.
In the first quarter of 2025, HIV product sales increased 6% year-over-year <a href="https://www.benzinga.com/general/biotech/25/04/44997817/gilead-sciences-stock-slips-after-mixed-q1-results-lowered-fy25-eps-guidance" target="_blank" rel="noreferrer noopener">to $4.59 billion</a>.
According to a media report in February, the Health and Human Services Department is considering substantial reductions in federal funding for <a href="https://www.benzinga.com/general/biotech/25/03/44395415/trump-administration-weighs-deep-cuts-to-domestic-hiv-prevention-programs-gilead-stock-slides" target="_blank" rel="noreferrer noopener">domestic HIV prevention</a>.
Mitchell Warren, executive director of HIV prevention group AVAC, says the CDC&#8217;s PrEP program could be reduced or cut. Launched last fall as a pilot program, it provides free medication to help prevent HIV.
GILD Price Action: GILD stock is up 2.19% at $111.41 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45791216/citi-to-cut-3500-tech-jobs-in-china-in-global-restructuring-spree" target="_blank" rel="noreferrer noopener">Citi To Cut 3,500 Tech Jobs In China In Global Restructuring Spree</a></li>
</ul>

Photo: Shutterstock

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.25%. Currently, Gilead Sciences has a market capitalization of $136.78 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,044.25 today based on a price of $109.96 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748875512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Reported Sunday, Gilead's Kite Presents Real-World Data At ASCO 2025 Supporting Outpatient Use Of Yescarta For R/R Large B-Cell Lymphoma With Comparable Safety And Efficacy

<ul>
<li>First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC –</li>
<li>Early Trend in Improvement in Overall Survival Observed</li>
</ul>

Reported Saturday, Gilead's TROP-2 ADC Trodelvy, In Combination With Keytruda, Shows Clinically Meaningful Survival Gains And Fewer Adverse Event-Related Discontinuations In ASCENT-04

Rumors

Watching Gilead Sciences; Hearing Investor Business Daily's SwingTrader Buys Stock

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

AMGN

MRNA

REGN

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Gilead Sciences Announces Topline Results From Phase 3 ASCENT-03 Study Of Trodelvy Met Its Primary Endpoint

Ratings for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $128.0, a high estimate of $140.00, and a low estimate of $117.00. This upward trend is evident, with the current average reflecting a 7.56% increase from the previous average price target of $119.00.
<img src="https://www.benzinga.com/files/images/story/2025/1747857620_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$117.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$126.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Gilead Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gilead Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Gilead Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Unveiling the Story Behind Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Gilead Sciences faced challenges, resulting in a decline of approximately -0.28% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Gilead Sciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 19.72%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.83%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average at 1.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Gilead Sciences Stock

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Gilead Sciencesto Hold

Press Releases

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Comments

Gilead Sciences

空売り

Gilead Sciences (NASDAQ:GILD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル